Alvircept sudotox

Drug Profile

Alvircept sudotox

Alternative Names: CD4 PE; CD4 PE40; CD4 pseudomonas exotoxin; CD4(178) PE40; sCD4 PE40; U 85855

Latest Information Update: 27 May 2003

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Pharmacia Corporation
  • Class Antineoplastics; Antivirals; Immunotoxins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 05 Apr 2000 Discontinued - Phase II for HIV infections treatment in USA (unspecified route)
  • 08 Nov 1994 A clinical study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top